Toby Eyre, MCBhB, MRCP, consultant hematologist at Oxford University Hospitals NHS Trust, discusses resistance to BTK inhibition in mantle cell lymphoma (MCL).
Toby Eyre, MCBhB, MRCP
Advertisement
Articles by Toby Eyre, MCBhB, MRCP
Advertisement
Latest Updated Articles
Dr. Eyre on Resistance to BTK Inhibition in MCLPublished: January 26th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5